New drug combo shows promise for untreated kidney cancer
NCT ID NCT01684397
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two drugs, pazopanib and bevacizumab, given one after the other in people with advanced kidney cancer that has spread. The goal is to find the best dose and see how well the combination works. About 51 patients who have not had prior treatment will take part. The drugs work by blocking blood flow to tumors and stopping cancer cell growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pazopanib hydrochloride and bevacizumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced kidney cancer that has spread, potentially improving how long the cancer is kept under control.
What could go wrong
This is an early-phase trial with only 51 participants, so results may not apply to everyone. The combination may cause serious side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karamanos Cancer Institute
Detroit, Michigan, 482018, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States